MJFF Provides Funding and EMA Supports Toxicology Strategy for Oncodesign Drug
What happened
The Michael J. Fox Foundation for Parkinson's Research confirmed support for Oncodesign Precision Medicine's program by providing an additional funding tranche. Concurrently, the European Medicines Agency supported the proposed long-term toxicology strategy for the drug OPM-201. Oncodesign also reported successful micronization of the active pharmaceutical ingredient and the manufacturing of the first technical batches of OPM-201 tablets.
From finanznachrichten.de
Why it matters
The funding supports the manufacturing of the drug product required for clinical advancement, and the support from the European Medicines Agency helps prepare for regulatory and clinical steps. The company plans to initiate a Phase 1b trial for OPM-201 in Parkinson's disease patients in 2027.
From finanznachrichten.de
Who's involved
Keep exploring
The entities involved
-
foundation
type of nonprofit organization
- FDA